WaveMan
WaveMan · Company
GURE · Gulf Resources, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

GURE Gulf Resources (GURE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Chemicals & allied products · CIK 0000885462
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
3
13F, latest reported quarter

Gulf Resources insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for GULF RESOURCES, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Miao Naihui
COO & Secretary
SELL
2023-12-21 SECtraded 2023-12-20
110,000
$275.0K
-80.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 8, 2022.
  • The trade is 607.2% of the 18,115 shares held after it.
  • 2 other insiders sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COO & Secretary Miao Naihui sold about $275.0K of GURE on Dec 20, 2023, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 3 funds added in the latest 13F quarter.
Liu Xiaobin
Chief Executive Officer
SELL
2023-12-21 SECtraded 2023-12-20
110,000
$275.0K
-80.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 12, 2022.
  • The trade is 607.2% of the 18,115 shares held after it.
  • 2 other insiders sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Liu Xiaobin sold about $275.0K of GURE on Dec 20, 2023, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 3 funds added in the latest 13F quarter.
Li Min
Chief Financial Officer
SELL
2023-12-21 SECtraded 2023-12-20
110,000
$275.0K
-80.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 15, 2022.
  • The trade is 607.2% of the 18,115 shares held after it.
  • 2 other insiders sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Li Min sold about $275.0K of GURE on Dec 20, 2023, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 3 funds added in the latest 13F quarter.
Zhang Tengfei
Director
SELL
2023-06-23 SECtraded 2023-06-22
2,000
$5.0K
-88.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 200.0% of the 1,000 shares held after it.
  • No other insider sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Zhang Tengfei sold about $5.0K of GURE on Jun 22, 2023; 3 funds added in the latest 13F quarter.
Ma Shengwei
Director
SELL
2022-12-21 SECtraded 2022-12-20
2,000
$6.0K
-90.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 200.0% of the 1,000 shares held after it.
  • No other insider sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ma Shengwei sold about $6.0K of GURE on Dec 20, 2022; 3 funds added in the latest 13F quarter.
14 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 9 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
3 funds bought in last quarter
below 99% of Pharma & Biotech
Revenue
+231.8% year over year
more than 90% of Pharma & Biotech
Margin
-172.8% net margin
below 63% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.7% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 79% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch GURE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-43.8%12M
-47%-10%+27%+64%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns GURE: institutional holders (13F)

13F holdings, latest reported quarter
CITADEL ADVISORS LLC
32,538 sh
$118.8K
TWO SIGMA INVESTMENTS, LP
14,652 sh
$53.5K
LANARK FINANCIAL, INC.
45 sh
$164
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC
10 sh
$36
Caitong International Asset Management Co., Ltd
3 sh
$11

Congress trades in GURE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

GURE planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

GURE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Nasdaq Composite Index Fund
$6.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 3 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

GURE financials

Revenue growth
+231.8%
XBRL, annual
Net margin
-172.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$30.7M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-134.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.05x
current debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
1.06x
TTM operating cash flow over current debt only, 2026-06-30
Return on equity
-32.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-27.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
-$785.5K
market value at close 2026-10-26 on 2026-09-29 shares, plus current debt only, 2026-06-30, minus cash 2024-09-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$25.4M$7.7M$30.0M$66.1M
Operating income-$8.6M-$22.2M-$11.9M$16.5M
Net income-$43.9M-$59.9M-$61.8M$10.1M
EPS (diluted)-32.95-54.88-58.16n/a
Operating cash flow$7.8M$675.8K-$32.8M$51.1M
Cashn/an/a$72.2Mn/a
SEC XBRL, fiscal years, as known on 2026-10-28

GURE Stock Sonar score 5/7 axes

Find similar shapesCompare

GURE ranks highest on growth (90th percentile) and financial health (78th), and lowest on institutional and government (1st), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
64
Inputs
  • Return on equity-32.4% · 65 pct, sector of 545
  • Return on assets-27.6% · 62 pct, sector of 691
  • Return on invested capitalthe filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Return on capital employedthe filed year and its quarters do not reconcile, so the trailing figure is withheld
Financial health
78
Inputs
  • Debt to equity0.05x · 62 pct, sector of 352
  • Cash flow to debt1.06x · 93 pct, sector of 371
Growth
90
Inputs
  • Revenue growth, YoY+231.8% · 90 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
1
Inputs
  • Funds adding, latest quarter3 · 1 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
44
Inputs
  • Short interest, % of float+0.7% · 84 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+53.4% · 4 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies